SCHEMBL18790110

SCHEMBL18790110

Cc1cccc(C)c1C(=O)N1CCC[C@H](C(=O)Nc2cccc(C(F)(F)F)c2)C1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBE2M P61081 5/20 0.51
▸ DCUN1D1 Q96GG9 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ LMNA P02545 3/20 0.45
▸ USP2 O75604 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ TRPV1 Q8NER1 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ HCRTR1 O43613 1/20 0.44
▸ HCRTR2 O43614 1/20 0.44
▸ GRIN2B Q13224 2/20 0.44
▸ RHOA P61586 1/20 0.43
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14960484 1.00 UBE2M (0.51) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL13326991 1.00 UBE2M (0.51) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL29726754 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL18790116 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL16280646 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL18609701 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL12160761 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL2579735 0.95 DCUN1D1 (0.48) UBE2MDCUN1D1KDM4EMEN1KMT2A
SCHEMBL12176191 0.92 ALDH1A1 (0.43) UBE2MDCUN1D1ALDH1A1EPHX2LMNA
SCHEMBL18532606 0.92 ALDH1A1 (0.43) UBE2MDCUN1D1ALDH1A1EPHX2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 — — EP disclosed
EP-3508477-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2019-07-10 — — EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 UBE2M 4268/4885DCUN1D1 1926/4885KDM4E 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback